4.4 Article

Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Pharmacology & Pharmacy

Lumasiran: First Approval

Lesley J. Scott et al.

Summary: Lumasiran is a drug developed for the treatment of primary hyperoxaluria type 1 by targeting a specific gene to inhibit the synthesis of toxic metabolites. It received approvals in the EU and USA, marking its global recognition.
Article Pediatrics

Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient

Caroline Kempf et al.

PEDIATRIC NEPHROLOGY (2020)

Article Medicine, Research & Experimental

Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning

Marine Le Dudal et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

Article Urology & Nephrology

Characteristics and Outcomes of Children with Primary Oxalosis Requiring Renal Replacement Therapy

Jerome Harambat et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)

Article Transplantation

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment

Pierre Cochat et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)

Article Transplantation

Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome

CS van Woerden et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)